Logo image of ETON

ETON PHARMACEUTICALS INC (ETON) Stock Fundamental Analysis

NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD

13.7  +0.09 (+0.66%)

After market: 13.7 0 (0%)

Fundamental Rating

4

Overall ETON gets a fundamental rating of 4 out of 10. We evaluated ETON against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ETON have multiple concerns. ETON is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ETON had negative earnings in the past year.
In the past year ETON had a positive cash flow from operations.
In the past 5 years ETON always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ETON reported negative operating cash flow in multiple years.
ETON Yearly Net Income VS EBIT VS OCF VS FCFETON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of ETON (-5.45%) is better than 74.87% of its industry peers.
Looking at the Return On Equity, with a value of -18.74%, ETON is in the better half of the industry, outperforming 72.82% of the companies in the same industry.
Industry RankSector Rank
ROA -5.45%
ROE -18.74%
ROIC N/A
ROA(3y)-14.67%
ROA(5y)-31.48%
ROE(3y)-30.22%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
ETON Yearly ROA, ROE, ROICETON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ETON's Gross Margin of 58.49% is fine compared to the rest of the industry. ETON outperforms 68.21% of its industry peers.
In the last couple of years the Gross Margin of ETON has grown nicely.
The Profit Margin and Operating Margin are not available for ETON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.67%
GM growth 5Y2.47%
ETON Yearly Profit, Operating, Gross MarginsETON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

2

2. Health

2.1 Basic Checks

ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
ETON has more shares outstanding than it did 1 year ago.
ETON has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ETON has a worse debt to assets ratio.
ETON Yearly Shares OutstandingETON Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ETON Yearly Total Debt VS Total AssetsETON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 2.73 indicates that ETON is not a great score, but indicates only limited risk for bankruptcy at the moment.
ETON's Altman-Z score of 2.73 is fine compared to the rest of the industry. ETON outperforms 73.33% of its industry peers.
ETON has a Debt/Equity ratio of 1.23. This is a high value indicating a heavy dependency on external financing.
ETON's Debt to Equity ratio of 1.23 is on the low side compared to the rest of the industry. ETON is outperformed by 73.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Altman-Z 2.73
ROIC/WACCN/A
WACC9.73%
ETON Yearly LT Debt VS Equity VS FCFETON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

ETON has a Current Ratio of 1.97. This is a normal value and indicates that ETON is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.97, ETON is doing worse than 61.54% of the companies in the same industry.
A Quick Ratio of 1.43 indicates that ETON should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.43, ETON is not doing good in the industry: 64.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.43
ETON Yearly Current Assets VS Current LiabilitesETON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for ETON have decreased strongly by -500.00% in the last year.
Looking at the last year, ETON shows a very strong growth in Revenue. The Revenue has grown by 40.86%.
ETON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 109.79% yearly.
EPS 1Y (TTM)-500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)40.86%
Revenue growth 3Y21.35%
Revenue growth 5Y109.79%
Sales Q2Q%116.95%

3.2 Future

ETON is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 90.90% yearly.
The Revenue is expected to grow by 43.60% on average over the next years. This is a very strong growth
EPS Next Y474%
EPS Next 2Y242.97%
EPS Next 3Y149.41%
EPS Next 5Y90.9%
Revenue Next Year105.03%
Revenue Next 2Y76.15%
Revenue Next 3Y61.76%
Revenue Next 5Y43.6%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ETON Yearly Revenue VS EstimatesETON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ETON Yearly EPS VS EstimatesETON Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ETON. In the last year negative earnings were reported.
ETON is valuated reasonably with a Price/Forward Earnings ratio of 10.02.
Based on the Price/Forward Earnings ratio, ETON is valued cheaper than 82.56% of the companies in the same industry.
ETON's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.19.
Industry RankSector Rank
PE N/A
Fwd PE 10.02
ETON Price Earnings VS Forward Price EarningsETON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ETON is valued a bit cheaper than 74.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7307.81
ETON Per share dataETON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

ETON's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ETON's earnings are expected to grow with 149.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y242.97%
EPS Next 3Y149.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ETON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ETON PHARMACEUTICALS INC

NASDAQ:ETON (6/18/2025, 8:00:01 PM)

After market: 13.7 0 (0%)

13.7

+0.09 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-04 2025-08-04
Inst Owners53.06%
Inst Owner Change8.77%
Ins Owners4.39%
Ins Owner Change-2.6%
Market Cap367.43M
Analysts82.22
Price Target29.58 (115.91%)
Short Float %3.24%
Short Ratio2.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-230.07%
Min EPS beat(2)-488.82%
Max EPS beat(2)28.68%
EPS beat(4)2
Avg EPS beat(4)-33.52%
Min EPS beat(4)-488.82%
Max EPS beat(4)394.12%
EPS beat(8)5
Avg EPS beat(8)15.47%
EPS beat(12)8
Avg EPS beat(12)14.28%
EPS beat(16)9
Avg EPS beat(16)-6.85%
Revenue beat(2)2
Avg Revenue beat(2)10.2%
Min Revenue beat(2)8.43%
Max Revenue beat(2)11.97%
Revenue beat(4)4
Avg Revenue beat(4)6.47%
Min Revenue beat(4)1.09%
Max Revenue beat(4)11.97%
Revenue beat(8)6
Avg Revenue beat(8)13.43%
Revenue beat(12)8
Avg Revenue beat(12)9.12%
Revenue beat(16)8
Avg Revenue beat(16)-6.79%
PT rev (1m)4.82%
PT rev (3m)12.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45.68%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.28%
Revenue NQ rev (1m)-2.47%
Revenue NQ rev (3m)-9.64%
Revenue NY rev (1m)2.5%
Revenue NY rev (3m)-2.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.02
P/S 7.6
P/FCF N/A
P/OCF 66.46
P/B 15.03
P/tB N/A
EV/EBITDA 7307.81
EPS(TTM)-0.04
EYN/A
EPS(NY)1.37
Fwd EY9.98%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)0.21
OCFY1.5%
SpS1.8
BVpS0.91
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.45%
ROE -18.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.49%
FCFM N/A
ROA(3y)-14.67%
ROA(5y)-31.48%
ROE(3y)-30.22%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.67%
GM growth 5Y2.47%
F-Score3
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Debt/EBITDA 576.77
Cap/Depr 426.09%
Cap/Sales 16.83%
Interest Coverage N/A
Cash Conversion 10632.7%
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.43
Altman-Z 2.73
F-Score3
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)372.49%
Cap/Depr(5y)366.77%
Cap/Sales(3y)13.75%
Cap/Sales(5y)36.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y474%
EPS Next 2Y242.97%
EPS Next 3Y149.41%
EPS Next 5Y90.9%
Revenue 1Y (TTM)40.86%
Revenue growth 3Y21.35%
Revenue growth 5Y109.79%
Sales Q2Q%116.95%
Revenue Next Year105.03%
Revenue Next 2Y76.15%
Revenue Next 3Y61.76%
Revenue Next 5Y43.6%
EBIT growth 1Y-445.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year716.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-261.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y169.71%
OCF growth 3YN/A
OCF growth 5YN/A